IMPROVED HBA1C, TOTAL DAILY INSULIN DOSE, AND TREATMENT SATISFACTION WITH INSULIN PUMP THERAPY COMPARED TO MULTIPLE DAILY INSULIN INJECTIONS IN PATIENTS WITH TYPE 2 DIABETES IRRESPECTIVE OF BASELINE C-PEPTIDE LEVELS
The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Abstract
Objective Fasting C-peptide levels are used to differentiate type 1 from type 2 diabetes (T2D), thereby determining eligibility for coverage of continuous subcutaneous insulin infusion (CSII) for patients with T2D.Methods A total of 168 patients (74 female/94 male, aged 55.5 ± 9.7 years) were randomized to CSII, and 163 patients (77 female/86 male, aged 56.4 ± 9.5 years) were randomized to multiple daily injections (MDI) of insulin and grouped by baseline C-peptide level: group A (≤183 pmol/L [≤0.55 ng/mL]); group B (>183 pmol/L [>0.55 ng/mL]). At 6 months, the MDI group crossed over to CSII. Within- and between-group comparisons were recorded at 6 and 12 months in the entire group and separately for those patients aged ≥65 years.Results CSII reduced hemoglobin A1c (A1c) equally in groups A ( P = .0006, P = .0022) and B ( P<.0001, P<.0001) at 6 and 12 months, respectively. There was an increase in weight in group A versus group B at 6 months but not 12 months ( P<.03). CSII therapy reduced total daily dose (TDD) of insulin and improved treatment satisfaction similarly in groups A and B. The results for patients aged ≥65 years displayed a similar trend as the entire group.Conclusion A1c, TDD of insulin, and treatment satisfaction improved for T2D patients using CSII versus MDI therapy, irrespective of baseline C-peptide level. A subgroup of patients aged ≥65 years displayed a similar trend. These results support abandoning C-peptide as a criterion for reimbursing CSII therapy in patients with diabetes.Abbreviations A1c = hemoglobin A1c; CMS = Centers for Medicare and Medicaid Services; CSII = continuous subcutaneous insulin infusion; DTSQ = Diabetes Treatment Satisfaction Questionnaire; MDI = multiple daily injections; RCT = randomized controlled trials; T1D = type 1 diabetes; T2D = type 2 diabetes; TDD = total daily dose.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“There are no data to suggest that measurement of C-peptide levels or antibodies predicts success with insulin pump therapy (170,171).”
From 7. Diabetes Technology: Standards of Care in Diabetes—2025 (2025) · cites this paper as [171]
In the citing paper
“Use of insulin pumps in insulin-requiring people with any type of diabetes may improve user satisfaction and simplify therapy (171,241).”
From 7. Diabetes Technology: Standards of Care in Diabetes—2025 (2025) · cites this paper as [171]
In the citing paper
“For people with diabetes judged to be clinically insulin deficient who are treated with an intensive insulin therapy, the presence or absence of measurable C-peptide levels does not correlate with response to therapy (171).”
From 7. Diabetes Technology: Standards of Care in Diabetes—2025 (2025) · cites this paper as [171]
Citations
Cites
Effects of Intensive Glucose Lowering in Type 2 Diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802743 · Cited by 7,888
Greenspan's Basic & Clinical Endocrinology
Gardner, D. G., & Shoback, D. (2007) · Medical Entomology and Zoology · Cited by 546
Prevalence of detectable C-peptide according to age at diagnosis and duration of type 1 diabetes
Davis, A. K., DuBose, S. N., Haller, M. J., Miller, K. M., DiMeglio, L. A., Bethin, K. E., Goland, R. S., Greenberg, E. M., Liljenquist, D. R., Ahmann, A. J., et al. (2015) · Diabetes Care · doi:10.2337/dc14-1952 · Cited by 261
Peters, A. L., Ahmann, A. J., Battelino, T., Evert, A., Hirsch, I. B., Murad, M. H., Winter, W. E., & Wolpert, H. (2016) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2016-2534 · Cited by 250
Reznik, Y., Cohen, O., Aronson, R., Conget, I., Runzis, S., Castaneda, J., & Lee, S. W. (2014) · The Lancet · doi:10.1016/s0140-6736(14)61037-0 · Cited by 233
Self-citationRiddle, M., Umpierrez, G., DiGenio, A., Zhou, R., & Rosenstock, J. (2011) · Diabetes Care · doi:10.2337/dc11-0632 · Cited by 219
Diabetes Treatment Satisfaction Questionnaire: (DTSQ)
Bradley, C. (2013) · doi:10.4324/9781315077369-16 · Cited by 205
Wang, L., Lovejoy, N. F., & Faustman, D. L. (2012) · Diabetes Care · doi:10.2337/dc11-1236 · Cited by 192
Pickup, J. C., Reznik, Y., & Sutton, A. J. (2017) · Diabetes Care · doi:10.2337/dc16-2201 · Cited by 92
Aronson, R., Reznik, Y., Conget, I., Castañeda, J. A., Runzis, S., Lee, S. W., Cohen, O., & for the OpT2mise Study Group (2016) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12642 · Cited by 65
Self-citationBradley, C. (2006) · Health and Quality of Life Outcomes · doi:10.1186/1477-7525-4-78 · Cited by 36
Effects of Intensive Glucose Lowering in Type 2 Diabetes
The University of North Carolina at Chapel Hill University Libraries (2020) · Carolina Digital Repository (University of North Carolina at Chapel Hill) · doi:10.17615/cmcv-xj36 · Cited by 12
Reznik, Y., Huang, S., & for the OpT2mise Study Group (2014) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2014.0261 · Cited by 10
Self-citationIs insulin the preferred treatment for HbA1c >9%?
Bloomgarden, Z. T. (2017) · Journal of Diabetes · doi:10.1111/1753-0407.12575 · Cited by 10
Cited by
Ahmad, E., Lim, S., Lamptey, R., Webb, D. R., & Davies, M. J. (2022) · The Lancet · doi:10.1016/s0140-6736(22)01655-5 · Cited by 1,120
7. Diabetes Technology: Standards of Medical Care in Diabetes—2022
American Diabetes Association Professional Practice Committee (2022) · Diabetes Care · doi:10.2337/dc22-s007 · Cited by 358
7. Diabetes Technology: Standards of Care in Diabetes—2025
American Diabetes Association Professional Practice Committee, ElSayed, N. A., McCoy, R. G., Aleppo, G., Balapattabi, K., Beverly, E. A., Briggs Early, K., Bruemmer, D., Echouffo-Tcheugui, J. B., Ekhlaspour, L., et al. (2025) · Diabetes Care · doi:10.2337/dc25-s007 · Cited by 348
7. Diabetes Technology: Standards of Care in Diabetes — 2023
ElSayed, N. A., Aleppo, G., Aroda, V. R., Bannuru, R. R., Brown, F. M., Bruemmer, D., Collins, B. S., Hilliard, M. E., Isaacs, D., Johnson, E. L., et al. (2023) · Diabetes Care · doi:10.2337/dc23-s007 · Cited by 301
7. Diabetes Technology: Standards of Care in Diabetes—2024
American Diabetes Association Professional Practice Committee, ElSayed, N. A., Aleppo, G., Bannuru, R. R., Bruemmer, D., Collins, B. S., Ekhlaspour, L., Hilliard, M. E., Johnson, E. L., Khunti, K., et al. (2024) · Diabetes Care · doi:10.2337/dc24-s007 · Cited by 281
Metadata
- Authors
- Vigersky, R. A., Huang, S., Cordero, T. L., Shin, J., Lee, S. W., Chhabra, H., Kaufman, F. R., & Cohen, O.
- Corresponding author
- Vigersky, Robert A.
- Venue
- Endocrine Practice
- Publisher
- Elsevier BV
- Published
- 2018-05
- Volume
- 24
- Issue
- 5
- Pages
- 446-452
- ISSN
- 1530-891X (ISSN-L)
- OpenAlex
- W2807347762
- Cited by
- 43
- References
- 14
- Citations by year
- 2026: 1 · 2025: 6 · 2024: 8 · 2023: 7 · 2022: 4 · 2021: 4 · 2020: 5 · 2019: 7 · 2018: 1
- FWCI
- 3.38
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- Locations
- Endocrine Practice (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Education
- Keywords
- type 2 diabetes, C-peptide, insulin pump therapy, total daily insulin dose, glycemic control, treatment satisfaction, older adults, insulin dose reduction, weight gain, Centers for Medicare and Medicaid Services, continuous glucose monitoring, multiple daily insulin injections, HbA1c
- MeSH terms
- Adult, Aged, Blood Glucose, C-Peptide, Diabetes Mellitus, Type 2, Female, Glycated Hemoglobin, Humans, Hypoglycemia, Hypoglycemic Agents, Injections, Subcutaneous, Insulin, Insulin Infusion Systems, Male, Middle Aged, Patient Satisfaction
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.